Laurent Arnould
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laurent Arnould has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Frédérique Penault-Llorca
Centre Jean Perrin, Clermont-Ferrand, France
4 shared publications - Bruno Coudert
Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France
3 shared publications - Anne Vincent-Salomon
Institut Curie, PSL University
2 shared publications C Migeon
Centre A Vautrin, Nancy 54000, France
2 shared publicationsCatherine Loustalot
Department of Surgery/Georges François Leclerc Comprehensive Cancer Care Centre, Dijon, France
2 shared publicationsF Penault-Llorca
Centre J Perrin, Clermont 63011, France
2 shared publications
Latest Publications
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e20523
Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.
E20523 Background: Recent advances in lung cancer biology underline that a diverse array of somatic genomic aberrations could drive cancer growth and be potential “drugable” targets. Advances in Next Generation Sequencing (NGS) technologies have improved the ability to detect potentially targetable mutations. However, the integration of NGS into clinical management in an individualized manner for lung cancer remains challenging. In this report, we evaluated the use of integrative clinical sequencing and molecular counseling in the treatment of patients with advanced metastatic lung cancer. Methods: In this single-center observational study, we performed dedicated a NGS panel studying 41 cancer-related genes in 50 consecutive patients with metastatic non-small-cell lung cancer between May 2012 and October 2014. Participants underwent integrative dedicated sequencing using TruSeq Custom Amplicon designs followed by molecular counseling. Results were discussed by a Molecular Tumor Board, which made recommendations to the treating physicians. Results: In this cohort of 50 patients, molecular analysis could be performed in 48 patients with a good quality check. One hundred and twenty-four mutations were detected. At least one mutation was found in 46 patients. In 58% of cases, the Molecular Tumor Board (MTB) was able to recommend treatment with a targeted agent based on the evaluation of the tumor genetic profile and treatment history. Eight patients (16%) were subsequently treated with an MTB-recommended targeted therapy; four patients experienced a clinical benefit with a partial response or stabilization lasting more than 4 months. Conclusions: In this single-center case series involving patients with metastatic non-small cell lung cancer in a reference cancer center, including integrative clinical sequencing data into clinical management was feasible, revealed potentially actionable findings in 58% of patients, and was associated with a treatment modification in 16% of patients. Further analysis with a larger number of patients and control group will be required to determine whether better clinical outcomes result from this approach.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e20523
Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.
E20523 Background: Recent advances in lung cancer biology underline that a diverse array of somatic genomic aberrations could drive cancer growth and be potential “drugable” targets. Advances in Next Generation Sequencing (NGS) technologies have improved the ability to detect potentially targetable mutations. However, the integration of NGS into clinical management in an individualized manner for lung cancer remains challenging. In this report, we evaluated the use of integrative clinical sequencing and molecular counseling in the treatment of patients with advanced metastatic lung cancer. Methods: In this single-center observational study, we performed dedicated a NGS panel studying 41 cancer-related genes in 50 consecutive patients with metastatic non-small-cell lung cancer between May 2012 and October 2014. Participants underwent integrative dedicated sequencing using TruSeq Custom Amplicon designs followed by molecular counseling. Results were discussed by a Molecular Tumor Board, which made recommendations to the treating physicians. Results: In this cohort of 50 patients, molecular analysis could be performed in 48 patients with a good quality check. One hundred and twenty-four mutations were detected. At least one mutation was found in 46 patients. In 58% of cases, the Molecular Tumor Board (MTB) was able to recommend treatment with a targeted agent based on the evaluation of the tumor genetic profile and treatment history. Eight patients (16%) were subsequently treated with an MTB-recommended targeted therapy; four patients experienced a clinical benefit with a partial response or stabilization lasting more than 4 months. Conclusions: In this single-center case series involving patients with metastatic non-small cell lung cancer in a reference cancer center, including integrative clinical sequencing data into clinical management was feasible, revealed potentially actionable findings in 58% of patients, and was associated with a treatment modification in 16% of patients. Further analysis with a larger number of patients and control group will be required to determine whether better clinical outcomes result from this approach.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e13116
The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
E13116 Background: Until recently, the molecular diagnosis of hereditary breast and ovarian cancer (HBOC) was mostly based on BRCA1 and 2 testing. The advent of next generation sequencing technologies and the recent discovery of new genes involved in HBOC progressively permitted the transfer of genomic capture targeting multiple candidate genes from research to diagnosis. However, the implication for the management of patients and their families has not been extensively studied. Methods: We studied 583 consecutive patients originated from Burgundy (France) fulfilling the criteria for BRCA testing using a next generation sequencing 25-gene panel including 20 candidate predisposition genes for breast and/or ovarian cancer. Results: A pathogenic BRCA1/2 mutation was found in 51 patients (9%). Besides, we found 37 pathogenic or likely pathogenic mutations in 10 different high to low-risk genes in 34 patients (6%). The most frequently mutated genes were CHEK2 (n = 12; 2 %), ATM (n = 9; 1.5 %), and PALB2 (n = 4; 0.6%). Three double-hits were found. Four mutations were found in MMR genes, and family history of Lynch syndrome could be found in 1/4 case only. Most of mutations were consistent with the spectrum of cancer(s) observed in the patient and/or family (89%), and at least one of them could be considered as an incidental finding. The analysis of clinical actionability performed among the 38 mutation-positive individuals other than BRCA enrolled in our clinics revealed that additional disease specific screening and/or prevention measurers beyond those based on personal and family history alone have been recommended in most of cases (84%). Conclusions: In conclusion, multigene panel testing is a powerful tool for identifying high to low-risk HBOC susceptibility genes. The penetrance and spectrum of cancer associated to these other genes remain sometimes undefined, and further collaborative work is crucially needed to address this question. The possibility of double hits should lead to careful genetic counseling.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e13116
The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
E13116 Background: Until recently, the molecular diagnosis of hereditary breast and ovarian cancer (HBOC) was mostly based on BRCA1 and 2 testing. The advent of next generation sequencing technologies and the recent discovery of new genes involved in HBOC progressively permitted the transfer of genomic capture targeting multiple candidate genes from research to diagnosis. However, the implication for the management of patients and their families has not been extensively studied. Methods: We studied 583 consecutive patients originated from Burgundy (France) fulfilling the criteria for BRCA testing using a next generation sequencing 25-gene panel including 20 candidate predisposition genes for breast and/or ovarian cancer. Results: A pathogenic BRCA1/2 mutation was found in 51 patients (9%). Besides, we found 37 pathogenic or likely pathogenic mutations in 10 different high to low-risk genes in 34 patients (6%). The most frequently mutated genes were CHEK2 (n = 12; 2 %), ATM (n = 9; 1.5 %), and PALB2 (n = 4; 0.6%). Three double-hits were found. Four mutations were found in MMR genes, and family history of Lynch syndrome could be found in 1/4 case only. Most of mutations were consistent with the spectrum of cancer(s) observed in the patient and/or family (89%), and at least one of them could be considered as an incidental finding. The analysis of clinical actionability performed among the 38 mutation-positive individuals other than BRCA enrolled in our clinics revealed that additional disease specific screening and/or prevention measurers beyond those based on personal and family history alone have been recommended in most of cases (84%). Conclusions: In conclusion, multigene panel testing is a powerful tool for identifying high to low-risk HBOC susceptibility genes. The penetrance and spectrum of cancer associated to these other genes remain sometimes undefined, and further collaborative work is crucially needed to address this question. The possibility of double hits should lead to careful genetic counseling.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e12082
Evolution of HER2 testing practices in breast cancer in France from 2005 to 2015: Results of the PartenHER national survey.
E12082 Background: For many years, French pathologists have been striving to standardize their practices and improve the quality of HER2 testing in breast cancer. The PartenHER survey aimed to assess how practices have evolved over the last decade. Methods: The PartenHER national survey is based on a questionnaire developed by a scientific committee and sent by postal mail in February 2015. Each French anatomo-cytopathology (ACP) labs received only one questionnaire. The formular was composed of 41 questions including typology of ACP labs, different technical conditions observed during pre-analytical, analytical, post-analytical steps, difficult-to-classify HER2 test results, quality controls, staff organization and training. Results: By 30 July 2015, 109 ACP labs (53% private, 47% public) regularly testing for HER2 and representing almost 620 pathologists (i.e. one third of the French pathologists) had completed the questionnaire. The study showed that in 2015, the immunohistochemistry (IHC) technique was performed by all labs, 42% of which were also performing the in situ hybridization (ISH) technique. The IHC technique was automated in 100 % of the labs, two thirds of them being automated for more than 10 years. ISH was automated in 83% of the structures and in place for more than 10 years in 20% of the cases and for five years in 56%. Several improvements in practices were also reported. Formalin is now the fixative used by 89% of labs. In 2015, 79% of the preformatted request forms were designed to collect the time of tissue removal (vs 12% in 2005), 87% were using a 3+ score reference tissue on each slide (vs 17% in 2005), 81% were tracking the HER2 overexpression rate mostly by using the HER-France national database, and 94% participated in proficiency testing, even though 42% of them had never been audited by an external authority. Conclusions: The PartenHER national survey showed that French pathologists, despite their diversity, have amended and standardized their practices regarding HER2 testing in breast cancer over the last 10 years. Further progress remains to be made, in particular to monitor the HER2 overexpression rate and resort to external audits.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e12082
Evolution of HER2 testing practices in breast cancer in France from 2005 to 2015: Results of the PartenHER national survey.
E12082 Background: For many years, French pathologists have been striving to standardize their practices and improve the quality of HER2 testing in breast cancer. The PartenHER survey aimed to assess how practices have evolved over the last decade. Methods: The PartenHER national survey is based on a questionnaire developed by a scientific committee and sent by postal mail in February 2015. Each French anatomo-cytopathology (ACP) labs received only one questionnaire. The formular was composed of 41 questions including typology of ACP labs, different technical conditions observed during pre-analytical, analytical, post-analytical steps, difficult-to-classify HER2 test results, quality controls, staff organization and training. Results: By 30 July 2015, 109 ACP labs (53% private, 47% public) regularly testing for HER2 and representing almost 620 pathologists (i.e. one third of the French pathologists) had completed the questionnaire. The study showed that in 2015, the immunohistochemistry (IHC) technique was performed by all labs, 42% of which were also performing the in situ hybridization (ISH) technique. The IHC technique was automated in 100 % of the labs, two thirds of them being automated for more than 10 years. ISH was automated in 83% of the structures and in place for more than 10 years in 20% of the cases and for five years in 56%. Several improvements in practices were also reported. Formalin is now the fixative used by 89% of labs. In 2015, 79% of the preformatted request forms were designed to collect the time of tissue removal (vs 12% in 2005), 87% were using a 3+ score reference tissue on each slide (vs 17% in 2005), 81% were tracking the HER2 overexpression rate mostly by using the HER-France national database, and 94% participated in proficiency testing, even though 42% of them had never been audited by an external authority. Conclusions: The PartenHER national survey showed that French pathologists, despite their diversity, have amended and standardized their practices regarding HER2 testing in breast cancer over the last 10 years. Further progress remains to be made, in particular to monitor the HER2 overexpression rate and resort to external audits.
- 21 November 2015
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 154 (3) , 543-555
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
Estrogen receptor 1 (ESR1) and ESR2 gene polymorphisms have been associated with endocrine-mediated physiological mechanisms, and inconsistently with breast cancer risk and outcomes, bone mineral density changes, and hot flushes/night sweats. DNA was isolated and genotyped for six ESR1 and two ESR2 single-nucleotide polymorphisms (SNPs) from tumor specimens from 3691 postmenopausal women with hormone receptor-positive breast cancer enrolled in the BIG 1-98 trial to receive tamoxifen and/or letrozole for 5 years. Associations with recurrence and adverse events (AEs) were assessed using Cox proportional hazards models. 3401 samples were successfully genotyped for five SNPs. ESR1 rs9340799(XbaI) (T>C) variants CC or TC were associated with reduced breast cancer risk (HR = 0.82,95 % CI = 0.67–1.0), and ESR1 rs2077647 (T>C) variants CC or TC was associated with reduced distant recurrence risk (HR = 0.69, 95 % CI = 0.53–0.90), both regardless of the treatments. No differential treatment effects (letrozole vs. tamoxifen) were observed for the association of outcome with any of the SNPs. Letrozole-treated patients with rs2077647 (T>C) variants CC and TC had a reduced risk of bone AE (HR = 0.75, 95 % CI = 0.58–0.98, P interaction = 0.08), whereas patients with rs4986938 (G>A) genotype variants AA and AG had an increased risk of bone AE (HR = 1.37, 95 % CI = 1.01–1.84, P interaction = 0.07). We observed that (1) rare ESR1 homozygous polymorphisms were associated with lower recurrence, and (2) ESR1 and ESR2 SNPs were associated with bone AEs in letrozole-treated patients. Genes that are involved in estrogen signaling and synthesis have the potential to affect both breast cancer recurrence and side effects, suggesting that individual treatment strategies can incorporate not only oncogenic drivers but also SNPs related to estrogen activity.
- 21 November 2015
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 154 (3) , 543-555
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
Estrogen receptor 1 (ESR1) and ESR2 gene polymorphisms have been associated with endocrine-mediated physiological mechanisms, and inconsistently with breast cancer risk and outcomes, bone mineral density changes, and hot flushes/night sweats. DNA was isolated and genotyped for six ESR1 and two ESR2 single-nucleotide polymorphisms (SNPs) from tumor specimens from 3691 postmenopausal women with hormone receptor-positive breast cancer enrolled in the BIG 1-98 trial to receive tamoxifen and/or letrozole for 5 years. Associations with recurrence and adverse events (AEs) were assessed using Cox proportional hazards models. 3401 samples were successfully genotyped for five SNPs. ESR1 rs9340799(XbaI) (T>C) variants CC or TC were associated with reduced breast cancer risk (HR = 0.82,95 % CI = 0.67–1.0), and ESR1 rs2077647 (T>C) variants CC or TC was associated with reduced distant recurrence risk (HR = 0.69, 95 % CI = 0.53–0.90), both regardless of the treatments. No differential treatment effects (letrozole vs. tamoxifen) were observed for the association of outcome with any of the SNPs. Letrozole-treated patients with rs2077647 (T>C) variants CC and TC had a reduced risk of bone AE (HR = 0.75, 95 % CI = 0.58–0.98, P interaction = 0.08), whereas patients with rs4986938 (G>A) genotype variants AA and AG had an increased risk of bone AE (HR = 1.37, 95 % CI = 1.01–1.84, P interaction = 0.07). We observed that (1) rare ESR1 homozygous polymorphisms were associated with lower recurrence, and (2) ESR1 and ESR2 SNPs were associated with bone AEs in letrozole-treated patients. Genes that are involved in estrogen signaling and synthesis have the potential to affect both breast cancer recurrence and side effects, suggesting that individual treatment strategies can incorporate not only oncogenic drivers but also SNPs related to estrogen activity.
- Open Access
- 8 May 2014
- Published by Springer Nature in Breast Cancer Research
- Vol. 16 (3) , R46
Polarity gene alterations in pure invasive micropapillary carcinomas of the breast
Introduction: Pure invasive micropapillary carcinoma (IMPC) is a special type of breast carcinoma characterised by clusters of cells presenting polarity abnormalities. The biological alterations underlying this pattern remain unknown. Methods: Pangenomic analysis (n = 39), TP53 (n = 43) and PIK3CA (n = 41) sequencing in a series of IMPCs were performed. A subset of cases was also analysed with whole-exome sequencing (n = 4) and RNA sequencing (n = 6). Copy number variation profiles were compared with those of oestrogen receptors and grade-matched invasive ductal carcinomas (IDCs) of no special type. Results: Unsupervised analysis of genomic data distinguished two IMPC subsets: one (Sawtooth/8/16) exhibited a significant increase in 16p gains (71%), and the other (Firestorm/Amplifier) was characterised by a high frequency of 8q (35%), 17q (20% to 46%) and 20q (23% to 30%) amplifications and 17p loss (74%). TP53 mutations (10%) were more frequently identified in the amplifier subset, and PIK3CA mutations (4%) were detected in both subsets. Compared to IDC, IMPC exhibited specific loss of the 6q16-q22 region (45%), which is associated with downregulation of FOXO3 and SEC63 gene expression. SEC63 and FOXO3 missense mutations were identified in one case each (2%). Whole-exome sequencing combined with RNA sequencing of IMPC allowed us to identify somatic mutations in genes involved in polarity, DNAH9 and FMN2 (8% and 2%, respectively) or ciliogenesis, BBS12 and BBS9 (2% each) or genes coding for endoplasmic reticulum protein, HSP90B1 and SPTLC3 (2% each) and cytoskeleton, UBR4 and PTPN21 (2% each), regardless of the genomic subset. The intracellular biological function of the mutated genes identified by gene ontology analysis suggests a driving role in the clinicopathological characteristics of IMPC. Conclusion: In our comprehensive molecular analysis of IMPC, we identified numerous genomic alterations without any recurrent fusion genes. Recurrent somatic mutations of genes participating in cellular polarity and shape suggest that they, together with other biological alterations (such as epigenetic modifications and stromal alterations), could contribute to the morphological pattern of IMPC. Though none of the individual abnormalities demonstrated specificity for IMPC, whether their combination in IMPC may have a cumulative effect that drives the abnormal polarity of IMPC needs to be examined further with in vitro experiments.
- 8 May 2014
- Published by Springer Nature in Breast Cancer Research
- Vol. 16 (3) , R46
Open AccessPolarity gene alterations in pure invasive micropapillary carcinomas of the breast
Introduction: Pure invasive micropapillary carcinoma (IMPC) is a special type of breast carcinoma characterised by clusters of cells presenting polarity abnormalities. The biological alterations underlying this pattern remain unknown. Methods: Pangenomic analysis (n = 39), TP53 (n = 43) and PIK3CA (n = 41) sequencing in a series of IMPCs were performed. A subset of cases was also analysed with whole-exome sequencing (n = 4) and RNA sequencing (n = 6). Copy number variation profiles were compared with those of oestrogen receptors and grade-matched invasive ductal carcinomas (IDCs) of no special type. Results: Unsupervised analysis of genomic data distinguished two IMPC subsets: one (Sawtooth/8/16) exhibited a significant increase in 16p gains (71%), and the other (Firestorm/Amplifier) was characterised by a high frequency of 8q (35%), 17q (20% to 46%) and 20q (23% to 30%) amplifications and 17p loss (74%). TP53 mutations (10%) were more frequently identified in the amplifier subset, and PIK3CA mutations (4%) were detected in both subsets. Compared to IDC, IMPC exhibited specific loss of the 6q16-q22 region (45%), which is associated with downregulation of FOXO3 and SEC63 gene expression. SEC63 and FOXO3 missense mutations were identified in one case each (2%). Whole-exome sequencing combined with RNA sequencing of IMPC allowed us to identify somatic mutations in genes involved in polarity, DNAH9 and FMN2 (8% and 2%, respectively) or ciliogenesis, BBS12 and BBS9 (2% each) or genes coding for endoplasmic reticulum protein, HSP90B1 and SPTLC3 (2% each) and cytoskeleton, UBR4 and PTPN21 (2% each), regardless of the genomic subset. The intracellular biological function of the mutated genes identified by gene ontology analysis suggests a driving role in the clinicopathological characteristics of IMPC. Conclusion: In our comprehensive molecular analysis of IMPC, we identified numerous genomic alterations without any recurrent fusion genes. Recurrent somatic mutations of genes participating in cellular polarity and shape suggest that they, together with other biological alterations (such as epigenetic modifications and stromal alterations), could contribute to the morphological pattern of IMPC. Though none of the individual abnormalities demonstrated specificity for IMPC, whether their combination in IMPC may have a cumulative effect that drives the abnormal polarity of IMPC needs to be examined further with in vitro experiments.
- Open Access
- 22 July 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 351
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
Until now, FISH has been the gold standard technique to identify HER2 amplification status in ambiguous cases of breast cancer. Alternative techniques have been developed to increase the capacities of investigating HER2 amplification status. The aims of this multicenter study in a large series of breast cancer patients were to prospectively compare the level of performance of CISH, SISH, and qPCR alternative techniques on paraffin-embedded core biopsies with “gold standard FISH” for evaluation of HER2 amplification status. This study was performed on 840 cases scored by immunohistochemistry (IHC): 0=317 (38%), 1+=183 (22%), 2+=109 (13%), 3+=231 (27%). Each of the 15 French centers participating in the study analyzed 56 breast carcinoma cases diagnosed on fixed paraffin-embedded core biopsies. HER2 amplification status was determined by commercially available FISH used as the reference technique with determination of the HER2/CEN17 ratio or HER2 copy number status. The alternative techniques performed on the same cases were commercially available SISH or CISH and a common qPCR method especially designed for the study including a set of 10 primer pairs: 2 for HER2 (exons 8 and 26), 5 to evaluate chromosome 17 polysomy TAOK1, UTP6, MRM1, MKS1, SSTR2 and 3 for diploidy control TSN, LAP3 and ADAMTS16. The concordance between IHC and FISH was 96% to 95% based on the HER2/CEN17 ratio (n=766) or HER2 copy number (n=840), respectively. The concordance of the alternative techniques with FISH was excellent: 97% and 98% for SISH (498 and 587 cases), 98% and 75% for CISH (108 and 204 cases) and 95% and 93% (699 and 773 cases) for qPCR based on the HER2/CEN17 ratio or HER2 copy number, respectively. Similarly, sensitivity ranged from 99% to 95% for SISH, 100% to 99% for CISH and 89% to 80% for qPCR. The concordance with FISH (ratio) in the 2+ cases was 89% for SISH, 100% for CISH and 93% for qPCR. These alternative techniques showed an excellent concordance with FISH in core biopsies allowing their use in routine clinical practice. This newly designed qPCR on paraffin-embedded core biopsies deserves special attention, as it is reliable, easy to perform and less expensive than ISH tests.
- 22 July 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 351
Open AccessSISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
Until now, FISH has been the gold standard technique to identify HER2 amplification status in ambiguous cases of breast cancer. Alternative techniques have been developed to increase the capacities of investigating HER2 amplification status. The aims of this multicenter study in a large series of breast cancer patients were to prospectively compare the level of performance of CISH, SISH, and qPCR alternative techniques on paraffin-embedded core biopsies with “gold standard FISH” for evaluation of HER2 amplification status. This study was performed on 840 cases scored by immunohistochemistry (IHC): 0=317 (38%), 1+=183 (22%), 2+=109 (13%), 3+=231 (27%). Each of the 15 French centers participating in the study analyzed 56 breast carcinoma cases diagnosed on fixed paraffin-embedded core biopsies. HER2 amplification status was determined by commercially available FISH used as the reference technique with determination of the HER2/CEN17 ratio or HER2 copy number status. The alternative techniques performed on the same cases were commercially available SISH or CISH and a common qPCR method especially designed for the study including a set of 10 primer pairs: 2 for HER2 (exons 8 and 26), 5 to evaluate chromosome 17 polysomy TAOK1, UTP6, MRM1, MKS1, SSTR2 and 3 for diploidy control TSN, LAP3 and ADAMTS16. The concordance between IHC and FISH was 96% to 95% based on the HER2/CEN17 ratio (n=766) or HER2 copy number (n=840), respectively. The concordance of the alternative techniques with FISH was excellent: 97% and 98% for SISH (498 and 587 cases), 98% and 75% for CISH (108 and 204 cases) and 95% and 93% (699 and 773 cases) for qPCR based on the HER2/CEN17 ratio or HER2 copy number, respectively. Similarly, sensitivity ranged from 99% to 95% for SISH, 100% to 99% for CISH and 89% to 80% for qPCR. The concordance with FISH (ratio) in the 2+ cases was 89% for SISH, 100% for CISH and 93% for qPCR. These alternative techniques showed an excellent concordance with FISH in core biopsies allowing their use in routine clinical practice. This newly designed qPCR on paraffin-embedded core biopsies deserves special attention, as it is reliable, easy to perform and less expensive than ISH tests.
- 1 May 2012
- Published by Elsevier in Laboratory Investigation
- Vol. 25 (5) , 675-682
Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH)
- 1 May 2012
- Published by Elsevier in Laboratory Investigation
- Vol. 25 (5) , 675-682
Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH)
- 1 June 2009
- Published by Elsevier in Annales de Pathologie
- Vol. 29 (3) , 216-222
Pièges diagnostiques en pathologie mammaire. Cas no6. Carcinome métaplasique de type adénosquameux de bas grade
- 1 June 2009
- Published by Elsevier in Annales de Pathologie
- Vol. 29 (3) , 216-222
Pièges diagnostiques en pathologie mammaire. Cas no6. Carcinome métaplasique de type adénosquameux de bas grade
- 1 June 2009
- Published by Elsevier in Annales de Pathologie
- Vol. 29 (3) , 205-210
Pièges diagnostiques en pathologie mammaire. Cas no 4. Adénose microglandulaire
- 1 June 2009
- Published by Elsevier in Annales de Pathologie
- Vol. 29 (3) , 205-210
Pièges diagnostiques en pathologie mammaire. Cas no 4. Adénose microglandulaire
- Open Access
- 1 November 2007
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (21) , 6404-6409
Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification
Purpose: Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) are used to determine human epidermal growth factor receptor-2 (HER-2) status and patient eligibility for trastuzumab therapy. Using FISH and IHC, we analyzed the relationship between pathologic complete response to trastuzumab-based neoadjuvant therapy and level of HER-2 amplification in locally advanced breast cancer. Experimental Design: Breast biopsies from 93 HER-2–positive patients treated with trastuzumab-based neoadjuvant therapy were centrally collected and analyzed retrospectively for HER-2 amplification using FISH and HER-2 overexpression using IHC. Tumors were classified by FISH as no, low, or high amplification. Biopsies were reassessed centrally by IHC and graded 0, 1+, 2+, or 3+. Results: HER-2 status of tumor samples as assessed by FISH and IHC correlated: 16 no amplification (11 IHC 1+ and 5 IHC 2+), 27 low amplification (26 IHC 3+ and 1 IHC 2+), and 50 high amplification (all IHC 3+). Trastuzumab-based neoadjuvant therapy achieved pathologic complete response in 35 of 93 (37.6%) tumors. Pathologic complete response rate in low- and high-amplification tumors was significantly higher than in no-amplification tumors (44% versus 6%; P < 0.004). Pathologic complete response rate in high-amplification tumors was significantly higher compared with low-amplification tumors (56% versus 22%; P < 0.005). In the subgroup of low- plus high-amplification tumors, no correlation was found between pathologic complete response rate and IHC score, treatment regimen, T or N stage, tumor grade, or hormonal receptors. Conclusions: This is the first study to show positive correlation between level of HER-2 amplification assessed by FISH and rate of pathologic complete response to trastuzumab-based neoadjuvant treatment.
- 1 November 2007
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (21) , 6404-6409
Open AccessPathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification
Purpose: Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) are used to determine human epidermal growth factor receptor-2 (HER-2) status and patient eligibility for trastuzumab therapy. Using FISH and IHC, we analyzed the relationship between pathologic complete response to trastuzumab-based neoadjuvant therapy and level of HER-2 amplification in locally advanced breast cancer. Experimental Design: Breast biopsies from 93 HER-2–positive patients treated with trastuzumab-based neoadjuvant therapy were centrally collected and analyzed retrospectively for HER-2 amplification using FISH and HER-2 overexpression using IHC. Tumors were classified by FISH as no, low, or high amplification. Biopsies were reassessed centrally by IHC and graded 0, 1+, 2+, or 3+. Results: HER-2 status of tumor samples as assessed by FISH and IHC correlated: 16 no amplification (11 IHC 1+ and 5 IHC 2+), 27 low amplification (26 IHC 3+ and 1 IHC 2+), and 50 high amplification (all IHC 3+). Trastuzumab-based neoadjuvant therapy achieved pathologic complete response in 35 of 93 (37.6%) tumors. Pathologic complete response rate in low- and high-amplification tumors was significantly higher than in no-amplification tumors (44% versus 6%; P < 0.004). Pathologic complete response rate in high-amplification tumors was significantly higher compared with low-amplification tumors (56% versus 22%; P < 0.005). In the subgroup of low- plus high-amplification tumors, no correlation was found between pathologic complete response rate and IHC score, treatment regimen, T or N stage, tumor grade, or hormonal receptors. Conclusions: This is the first study to show positive correlation between level of HER-2 amplification assessed by FISH and rate of pathologic complete response to trastuzumab-based neoadjuvant treatment.